Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 31-40 of 81 for Lymphoma

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. A Study to Provide Access to CTL019 Out of Specification Managed Access Program (MAP) for ALL or DLBCL Patients

    Jacksonville, FL, Scottsdale/Phoenix, AZ, Rochester, MN

  3. A Study to Evaluate Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/ Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

    Rochester, MN

  4. A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  5. Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

    Rochester, MN

  6. Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  7. Coronary CTA for Radiation Therapy Planning in Lymphoma Patients

    Rochester, MN

  8. Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

    Scottsdale/Phoenix, AZ, Rochester, MN

  9. Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

    Rochester, MN

  10. PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

    Jacksonville, FL, Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer